Novo Nordisk A/S (NYSE:NVO) Downgraded to “Hold” Rating by TD Cowen

Novo Nordisk A/S (NYSE:NVO) was downgraded by stock analysts at TD Cowen from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday. They presently have a $42.00 target price on the stock. TD Cowen’s target price would indicate a potential upside of 5.60% from the company’s current price.

NVO has been the topic of a number of other reports. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Citigroup began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S Trading Up 3.1%

NVO opened at $39.77 on Tuesday. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The business’s 50 day moving average price is $51.18 and its 200 day moving average price is $52.24. The stock has a market capitalization of $177.59 billion, a PE ratio of 11.46 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently modified their holdings of the company. Capital International Investors grew its position in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Novo Nordisk A/S by 6.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the period. Franklin Resources Inc. raised its holdings in shares of Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares during the period. Morgan Stanley raised its stake in Novo Nordisk A/S by 3.5% in the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after acquiring an additional 428,660 shares during the period. Finally, Folketrygdfondet grew its stake in shares of Novo Nordisk A/S by 1.2% during the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after buying an additional 117,370 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo agreed to sell its branded GLP‑1 drugs (Wegovy and Ozempic) through Hims & Hers’ telehealth platform, ending the recent patent lawsuit — this gives Novo a direct digital channel to Hims’ large user base and removes a source of unregulated compounded competition. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Novo launched a share repurchase programme (part of up to DKK 15bn over 12 months), which supports the stock via buyback-driven EPS support and signals management confidence in cash generation. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Analysts note the deal helps Novo regain a controlled digital distribution route (access to millions of telehealth users) and preserves branded economics while curbing compounding competitors — a constructive repositioning if adoption through telehealth proves durable. Novo’s Quiet Comeback Begins
• Neutral Sentiment: Brokerage consensus remains cautious (consensus “Hold”); analysts are updating estimates for FY2026 and watching GLP‑1 pricing and volume trends — this tempers immediate upside from the Hims deal. Novo Nordisk A/S (NYSE:NVO) Given Consensus Recommendation of “Hold” by Brokerages
• Negative Sentiment: Market commentary highlights material recent share-price erosion (nearly $50bn in market cap loss in a month) as competitive pressure from rivals (e.g., Lilly) and potential price cuts across the GLP‑1 franchise weigh on growth expectations and valuation. NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.